share_log

Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies

Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies

Twist Bioscience与Astellas联手开发抗癌靶向抗体
Benzinga Real-time News ·  2022/05/09 13:58
  • Twist Bioscience Corporation (NASDAQ:TWST) has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc (OTC:ALPMF) to conduct research activities to identify and optimize proprietary Twist antagonist antibodies.
  • The antibodies will target an undisclosed checkpoint inhibitor pathway in the tumor microenvironment as potential therapeutic development candidates. 
  • Ligands in this pathway are found in relatively high concentrations in the tumor microenvironment. 
  • Also Read: Twist Bioscience Inks Antibody Discovery Pact With MediSix Therapeutics.
  • Blocking the receptor's activation can markedly enhance anti-tumor immunity with other Astellas therapies, including chimeric antigen receptor-based technologies combined with Universal Donor Cells. 
  • Astellas will have the exclusive option to license any development candidates generated as part of the collaboration.
  • Under the terms of the agreement, Twist will receive an upfront payment from Astellas and an additional payment upon the exercise of the licensing option. 
  • Twist will receive payments connected to success-based clinical milestones and sales-based royalty payments for each licensed product. 
  • Specific deal terms were not disclosed.
  • Astellas will be responsible for developing, manufacturing, and commercializing any licensed products.
  • Price Action: TWST shares are down 11.2% at $27.87 during the market session on the last check Monday.
  • 特威斯特生物科学公司纳斯达克(股票代码：TWST)已与以下公司签订研究合作和独家选项许可协议阿斯特拉斯制药公司(场外交易代码：ALPMF)开展研究活动，以识别和优化专利的Twist拮抗剂抗体。
  • 这些抗体将靶向肿瘤微环境中一个未披露的检查点抑制因子途径，作为潜在的治疗开发候选。
  • 该途径中的配体在肿瘤微环境中的浓度相对较高。
  • 另请阅读： Twist Bioscience墨水公司与MediSix Treateutics签署抗体发现协议.
  • 阻断受体的激活可以显著增强其他Astellas疗法的抗肿瘤免疫能力，包括基于嵌合抗原受体的技术与通用供体细胞相结合。
  • 作为合作的一部分，Astellas将拥有独家许可任何开发候选者的选择权。
  • 根据协议条款，Twist将从Astellas获得预付款，并在行使许可选择权时获得额外付款。
  • Twist将获得与基于成功的临床里程碑相关的付款，以及每个授权产品的基于销售的版税付款。
  • 具体的交易条款没有披露。
  • Astellas将负责任何许可产品的开发、制造和商业化。
  • 价格行动：在周一尾盘交易中，TWST股价下跌11.2%，至27.87美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发